Jenni Ilomaki

Dr. Jenni Ilomaki


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2019 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
RORichard Ofori-Asenso
Richard Ofori-Asenso
KCKen L. Chin
Ken L. Chin
MMMohsen Mazidi
Mohsen Mazidi
EZElla Zomer
Ella Zomer
JIJenni Ilomaki
Jenni Ilomaki
DLDanny Liew
Danny Liew
The increasing average life expectancy has contributed to aging of the world’s population.1 By 2050, approximately 21.3% of the global population will be 60 years or older,2 up from 9.2% in 1990. Frailty, a clinical syndrome characterized by marked vulnerability due to decline in reserve and function across multiple physiologic systems, is common among older people.3,4 Frailty manifests as the inability to tolerate stressful events and has been associated with adverse outcomes, such as falls,5 delirium,6 institutionalization,7 incident disability,8 and mortality.9 Frailty is also an independent risk factor for poor outcomes after surgery (eg, prolonged hospitalizations, increased susceptibility to deconditioning, and faster functional decline)10 and is associated with higher health care use11 and corresponding costs.12 There is a growing interest among stakeholders in aged care to better understand the patterns and determinants of frailty.13

1 June 2018 in JACC
Verified
Journal Article
Open access
MKMikhail Kosiborod
Mikhail Kosiborod
CLCarolyn S.P. Lam
Carolyn S.P. Lam
SKShun Kohsaka
Shun Kohsaka
DKDae Jung Kim
Dae Jung Kim
AKAvraham Karasik
Avraham Karasik
DMDianna Magliano
Dianna Magliano
Randomized trials demonstrated a lower risk of cardiovascular (CV) events with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in patients with type 2 diabetes (T2D) at high CV risk. Prior real-world data suggested similar SGLT-2i effects in T2D patients with a broader risk profile, but these studies focused on heart failure and death and were limited to the United States and Europe. The purpose of this study was to examine a broad range of CV outcomes in patients initiated on SGLT-2i versus other glucose-lowering drugs (oGLDs) across 6 countries in the Asia Pacific, the Middle East, and North American regions. New users of SGLT-2i and oGLDs were identified via claims, medical records, and national registries in South Korea, Japan, Singapore, Israel, Australia, and Canada. Propensity scores for SGLT-2i initiation were developed in each country, with 1:1 matching. Hazard ratios (HRs) for death, hospitalization for heart failure (HHF), death or HHF, MI, and stroke were assessed by country and pooled using weighted meta-analysis. After propensity-matching, there were 235,064 episodes of treatment initiation in each group; ∼27% had established CV disease. Patient characteristics were well-balanced between groups. Dapagliflozin, empagliflozin, ipragliflozin, canagliflozin, tofogliflozin, and luseogliflozin accounted for 75%, 9%, 8%, 4%, 3%, and 1% of exposure time in the SGLT-2i group, respectively. Use of SGLT-2i versus oGLDs was associated with a lower risk of death (HR: 0.51; 95% confidence interval [CI]: 0.37 to 0.70; p < 0.001), HHF (HR: 0.64; 95% CI: 0.50 to 0.82; p = 0.001), death or HHF (HR: 0.60; 95% CI: 0.47 to 0.76; p < 0.001), MI (HR: 0.81; 95% CI: 0.74 to 0.88; p < 0.001), and stroke (HR: 0.68; 95% CI: 0.55 to 0.84; p < 0.001). Results were directionally consistent across both countries and patient subgroups, including those with and without CV disease. In this large, international study of patients with T2D from the Asia Pacific, the Middle East, and North America, initiation of SGLT-2i was associated with a lower risk of CV events across a broad range of outcomes and patient characteristics. (Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors [CVD-REAL]; NCT02993614).

19 October 2018 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
SLSamanta Lalic
Samanta Lalic
JIJenni Ilomaki
Jenni Ilomaki
JBJ. Simon Bell
J. Simon Bell
MKMaarit Jaana Korhonen
Maarit Jaana Korhonen
NGNatasa Gisev
Natasa Gisev
Aims: The aims of the current study were to determine the prevalence and incidence of prescription opioid analgesic use in Australia and compare the characteristics of people with and without cancer initiating prescription opioid analgesics.Methods: A retrospective population‐based study was conducted using the random 10% sample of adults who were dispensed prescription opioid analgesics in Australia between July 2013 and June 2017 through the Pharmaceutical Benefits Scheme. Poisson regression was used to calculate rate ratios (RR) for opioid prevalence and incidence. The characteristics of people initiating opioids, including type of opioid initiated, total oral morphine equivalents dispensed, prescriber speciality, medical comorbidities, and past analgesic and benzodiazepine use, were compared for people with and without cancer.Results: Opioid prevalence increased {RR = 1.006 [95% confidence interval (CI) 1.004, 1.008]}, while incidence decreased [RR = 0.977 (95% CI 0.975,0.979)] from 2013/2014 to 2016/2017. There were between 287 677 and 307 772 prevalent users each year. In total, 769 334 adults initiated opioids between 2013/2014 and 2016/2017, and half of these initiations were by general practitioners. Initiation with a strong opioid occurred in 55.8% of those with cancer and 28.2% of those without cancer.Conclusion: Rates of opioid use have remained high since 2013, with approximately 3 million adults using opioids and over 1.9 million adults initiating opioids each year. Between 2013 and 2017, opioid prevalence has slightly increased but incidence has decreased. People without cancer account for the majority of opioid use and are more likely to be initiated on short‐acting and weak opioids. Initiation of strong opioids has increased over time, reinforcing concerns about increased use and the harms associated with strong opioids in the community.

20 August 2015 in Current Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
JIJenni Ilomaki
Jenni Ilomaki
NJNatali Jokanovic
Natali Jokanovic
ETEdwin Tan
Edwin Tan
ELEija Lonnroos
Eija Lonnroos
There is uncertainty in relation to the effect of alcohol consumption on the incidence of dementia and cognitive decline. This review critically evaluated published systematic reviews on the epidemiology of alcohol consumption and the risk of dementia or cognitive decline. MEDLINE, EMBASE and PsycINFO were searched from inception to February 2014. Systematic reviews of longitudinal observational studies were considered. Two reviewers independently completed the 11-item Assessment of Multiple Systematic Reviews (AMSTAR) tool to assess the quality. We identified three moderate quality systematic reviews (AMSTAR score 4-6) that included a total of 45 unique studies. Two of the systematic reviews encompassed a meta-analysis. Light to moderate drinking may decrease the risk of Alzheimer’s disease (AD) (pooled risk ratio [RR] 0.72; 95% confidence interval [CI] 0.61-0.86) and dementia (RR 0.74; 95%CI 0.61-0.91) whereas heavy to excessive drinking does not affect the risk (RR 0.92; 95%CI 0.59-1.45 and RR 1.04; 95%CI 0.69-1.56, respectively). One systematic review identified two studies that reported a link between alcohol consumption and the development of AD. No systematic review categorised former drinkers separately from lifetime abstainers in their analysis. Definitions of alcohol consumption, light to moderate drinking and heavy-excessive drinking varied and drinking patterns were not considered. Moderate quality (AMSTAR score 4-6) systematic reviews indicate that light to moderate alcohol consumption may protect against AD and dementia. However, the importance of drinking patterns and specific beverages remain unknown. There is insufficient evidence to suggest abstainers should initiate alcohol consumption to protect against dementia.

1 November 2016 in Journal of the American Medical Directors Association
Verified
Journal Article
Closed access
SLSamanta Lalic
Samanta Lalic
Janet SluggettJanet Sluggett
Janet Sluggett
JIJenni Ilomaki
Jenni Ilomaki
BWBarbara C. Wimmer
Barbara C. Wimmer
ETEdwin Tan
Edwin Tan
JBJ. Simon Bell
J. Simon Bell

1 February 2017 in Pharmacological Research
Verified
Journal Article
Closed access
Janet SluggettJanet Sluggett
Janet Sluggett
JIJenni Ilomaki
Jenni Ilomaki
KSKarla L. Seaman
Karla L. Seaman
MCMegan Corlis
Megan Corlis
JBJ Simon Bell
J Simon Bell